about
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedemaThe DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis.Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models.Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 casesThe neurofibromatosis type 2 gene is mutated in perineurial cell tumors: a molecular genetic study of eight cases.Malignant ectomesenchymoma: genetic profile reflects rhabdomyosarcomatous differentiation.Posttransplant Epstein-Barr virus-associated myogenic tumors: case report and review of the literature.MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumoursDeep sequencing reveals microRNAs predictive of antiangiogenic drug responseWhat are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans.Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.Clinical presentation, pathological features and natural course of metastatic uveal melanoma, an orphan and commonly fatal disease.Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features.KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs).Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation.New targets and therapies for gastrointestinal stromal tumors.Volatile organic compounds in gastrointestinal stromal tumour tissue originating from patient-derived xenografts.A unique occurrence of a cerebral atypical teratoid/rhabdoid tumor in an infant and a spinal canal primitive neuroectodermal tumor in her father.Primary myxoid mesenchymal tumour with intracranial location: report of a case with a EWSR1-ATF1 fusion.A precision therapy against cancers driven by KIT/PDGFRA mutations.Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients.Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE".Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors.Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases.Expression and significance of HER family receptors in neuroblastic tumors.Periventricular heterotopia in a boy with interstitial deletion of chromosome 4p.
P50
Q27851995-C88BDEC4-9847-4105-B565-D488FD8BB4FDQ33556211-A346C73B-529F-4207-9EB9-16DB473A5CA4Q34352283-A666D7D4-1B04-4D59-8AEA-524F8AF86059Q35555471-985B8D53-80D7-41BD-B96C-B1A40BE94EBBQ35745870-CDA18608-E5C1-4CEE-A9E4-5C1539F13B1EQ35842044-B7F7FD6E-0287-4C05-9E70-5F8EEC737619Q37016905-5C3F1BD7-4803-4105-9078-5319FA73790DQ37053934-A85D0F01-354E-4DDB-A04E-AC11CFA55955Q37182248-D6760D15-13E8-4B7F-87E7-2FAD466314FDQ37277227-17F6B3CC-A86A-49E3-A671-29FE6928FB64Q37342226-0BE885B0-ED35-4EC2-ADAF-16565CEDA527Q37778380-FAC523D9-1F84-4D0E-B0B5-F5E859D5A408Q38375877-5773847D-FCFF-4962-B618-A81C93CFA147Q39003171-DE2ED5A6-39FC-498D-8C74-FF9BB696A6D4Q39493276-2C26A72A-AD0F-4414-ABC6-348819470BBDQ39511054-7F449078-37F2-4CCC-A895-AC680B7E4A42Q39840653-AF4C4D29-FCA0-45C9-ADD8-580B12FE3447Q39939627-1EA6ADFF-5A27-4BE8-8D86-0373CB822004Q42726968-E9BF2684-7E88-4176-A6E2-FD7C488C5581Q42946212-9A82B2C8-C129-4E0E-853A-6DFFF1B3570CQ43474613-1B6395E8-7A3C-4EAC-A072-00F2F4EFFD03Q44006478-EA167E69-CF89-419F-9D0D-0047F6529391Q44031590-4151890D-288A-40B6-B26A-2C122D9604D6Q44394114-FBC739BC-C5CC-4488-B160-BA4A08539DA7Q46470985-DFEA5C27-E57D-492C-A1C8-71705DDD0DF9Q46816600-3E0F1558-FE46-4D16-B695-49C2683BDAEBQ47432725-D4E72933-1944-473B-9984-CBFF8A398EBEQ47917340-F25131B8-1ABC-47F9-B0A6-42D29B9B910DQ47994506-61E4EFF3-238D-4105-A869-5F3BF3384160Q48294211-ACEB879F-1B8B-4BB1-9818-823A1CB7C942Q48380159-7EAB75F3-B5A6-4781-A18D-54EE5DF46FA1Q48536333-9CD04874-43EF-4876-AB97-6C515A4299D1Q49092135-7D375FB0-0764-48D2-9526-732ADEA4A660Q49793433-AE0EDE06-BD7B-43C8-97BA-53F585A13ACBQ49820833-336C6919-67EC-4F5C-B7C4-C26BEBDE7B3AQ50027354-01819C5C-D704-4E83-AA83-EA4BEF06D82EQ50985599-A69A39B5-E6C3-4EF6-BD4A-51991E353900Q51716773-684D0EBC-2282-4D51-8363-54DDA437E202Q51892060-DEFA8247-545D-4BF3-9800-AD5BA81232DDQ51894328-0852ABE6-53FB-4A8B-B0B0-0380FBC045DF
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Agnieszka Wozniak
@ast
Agnieszka Wozniak
@en
Agnieszka Wozniak
@es
Agnieszka Wozniak
@nl
type
label
Agnieszka Wozniak
@ast
Agnieszka Wozniak
@en
Agnieszka Wozniak
@es
Agnieszka Wozniak
@nl
prefLabel
Agnieszka Wozniak
@ast
Agnieszka Wozniak
@en
Agnieszka Wozniak
@es
Agnieszka Wozniak
@nl
P106
P1153
7006222231
P21
P31
P496
0000-0001-9726-144X